{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:50Z","timestamp":1792008110661,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JCR Pharmaceuticals Co.,Ltd"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ymgme.2020.04.003","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T22:09:48Z","timestamp":1588284588000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II\/III clinical studies"],"prefix":"10.1016","volume":"130","author":[{"given":"Kimitoshi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Tozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.04.003_bb0005","series-title":"The Metabolic & Molecular Bases of Inherited Diseases","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"issue":"1","key":"10.1016\/j.ymgme.2020.04.003_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2020.04.003_bb0015","series-title":"Inherited Dysmetabolic Syndromes. 2nd Ed. [in Japanese]","first-page":"467","article-title":"Fabry disease","author":"Kobayashi","year":"2012"},{"issue":"1","key":"10.1016\/j.ymgme.2020.04.003_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ymgme.2020.04.003_bb0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2020.04.003_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.ymgme.2020.04.003_bb0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.ymgme.2020.04.003_bb0040","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2020.04.003_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymgme.2018.07.009","article-title":"Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease","volume":"125","author":"Morimoto","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2020.04.003_bb0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jcph.262","article-title":"First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects","volume":"54","author":"Kim","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ymgme.2020.04.003_bb0065","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/gim.2014.28","article-title":"Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1","volume":"16","author":"Tsuboi","year":"2014","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2020.04.003_bb0070","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gim.2012.39","article-title":"Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)","volume":"14","author":"Tsuboi","year":"2012","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2020.04.003_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/CCLM.2010.048","article-title":"Determination of globotriaosylceramide in plasma and urine by mass spectrometry","volume":"48","author":"Kr\u00fcger","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ymgme.2020.04.003_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.ymgme.2020.04.003_bb0085","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"447","key":"10.1016\/j.ymgme.2020.04.003_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2020.04.003_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2020.04.003_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.ymgme.2020.04.003_bb0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"WL","year":"2009","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.ymgme.2020.04.003_bb0115","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J. Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:25:21Z","timestamp":1761089121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220301098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1096719220301098"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.04.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II\/III clinical studies","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}